The study aims to identify individuals with mutations in Parkinson's disease-associated genes for further analysis.
Centogene said it will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene.
The companies will work together to identify the genetic mutations that cause the rare genetic lysosomal storage disorder alpha mannosidosis.
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
Centogene will help Aldeyra identify patients with Sjögren-Larsson Syndrome, a rare genetic disease for which Aldeyra is developing a treatment.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Under a new agreement, Centogene will integrate its CentoMD database of phenotype/genotype variants of rare diseases into the Qiagen bioinformatics platform.
Centogene said it will use the funds to accelerate growth and expansion in the areas of genetic testing, pharmaceutical collaborations, and big-data solutions.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.